Navigation Links
Quest Diagnostics Encourages Denver Area Residents to Enroll in Historic American Cancer Society Prevention Study November 8th - 19th

DENVER, Nov. 8, 2011 /PRNewswire/ -- Quest Diagnostics joined the American Cancer Society today to encourage Denver-area residents to participate in the American Cancer Society's historic Cancer Prevention Study - 3 (CPS-3).  The Denver enrollment period for this national, longitudinal study is between November 8 and 19, 2011. The CPS-3 Study focuses on uncovering the lifestyle, environmental and genetic factors that influence cancer risk by following 300,000 adults over the course of 20 years. The American Cancer Society and Quest Diagnostics are hoping to recruit approximately 1,000 Denver residents into the study.  

"Quest Diagnostics applauds and thanks the American Cancer Society for pursuing the knowledge necessary to fight cancer for future generations, and we are proud to play a role in the important research that will inform that fight," said Laure Park, Vice President Communications and Investor Relations and Corporate Citizenship Officer for Quest Diagnostics. "We encourage Denver area residents to enroll in CPS-3, and join with us in supporting the American Cancer Society as they work to create more birthdays, both today and tomorrow."

To raise awareness of the CPS-3 Denver area November enrollment opportunity, Denver Nuggets Coach George Karl, Quest Diagnostics Denver Medical Director Ralph Giorno, M.D., and American Cancer Society CPS-3 Principal Investigator Alpa Patel, PhD, held a press conference today at the Quest Diagnostics Denver laboratory and patient service center, calling on the community to participate.  Also in attendance was Diana Dreman, Miss Colorado, who has committed to a campaign in support of the American Cancer Society during her 2011 reign.

"We seek men and women between the ages of 30 and 65 who have never been diagnosed with cancer to participate in the CPS-3 study," said Dr. Patel. "A better understanding of the factors that contribute to cancer is the first step in our mission to cure cancer for future generations."

Researchers will use the data from CPS-3 to build on evidence from a series of American Cancer Society studies that began in the 1950s that collectively have involved millions of volunteer participants. Prior cancer prevention studies have confirmed the link between cigarette smoking and lung cancer, demonstrated the link between larger waist size and increased death rates from cancer and other causes, and showed the considerable impact of air pollution on heart and lung conditions.

Quest Diagnostics is the world's leader in cancer diagnostics, and the American Cancer Society is the company's employee-selected national charity. In addition to partnering with the American Cancer Society on CPS-3 since its launch in 2006, Quest Diagnostics is also the 'Get Regular Health Checks' national sponsor of Choose You®, the American Cancer Society's movement that inspires women to make healthy lifestyle choices to help prevent cancer.

To learn more about the CPS-3 study or to make an appointment at a Quest Diagnostics Denver area patient service center to participate, visit

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at Follow us at and

About the American Cancer Society

The American Cancer Society combines an unyielding passion with nearly a century of experience to save lives and end suffering from cancer. As a global grassroots force of more than three million volunteers, we fight for every birthday threatened by every cancer in every community. We save lives by helping people stay well by preventing cancer or detecting it early; helping people get well by being there for them during and after a cancer diagnosis; by finding cures through investment in groundbreaking discovery; and by fighting back by rallying lawmakers to pass laws to defeat cancer and by rallying communities worldwide to join the fight. As the nation's largest non-governmental investor in cancer research, contributing about $3.4 billion, we turn what we know about cancer into what we do. As a result, more than 11 million people in America who have had cancer and countless more who have avoided it will be celebrating birthdays this year. To learn more about us or to get help, call us any time, day or night, at 1-800-227-2345 or visit

SOURCE Quest Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. "Tomorrows Health" TV Series Showing the Life Science Industrys Quest to Save and Improve Lives, to Air on Select NBC Stations
2. Quest Diagnostics Initiates CEO Succession Process
3. Diamonds, silver and the quest for single photons
4. Maryland Stem Cell Research Commission Issues 2012 Requests for Applications (RFAs)
5. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
6. HDS International Comments on Front-end Carbon Sequestration Technologies
7. Quest Diagnostics and Genomic Vision Form Strategic Collaboration to Develop Genome-based Laboratory Tests
8. Clinical Genomics Extends Strategic Alliance for Colorectal Cancer Testing Development with Quest Diagnostics
9. GEN point of view article questions reported costs of drug R&D
10. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
11. FDA Requests Input on Development of User Fee Program for Biosimilar and Interchangeable Biological Products
Post Your Comments:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):